检验医学与临床2024，Vol.21Issue(13)：1864-1869,6.DOI:10.3969/j.issn.1672-9455.2024.13.009
miR-22表达水平与非小细胞肺癌患者放化疗敏感性的关系
Relationship between miR-22 expression level and chemoradiotherapy sensitivity in patients with non-small cell lung cancer
摘要
Abstract
Objective To investigate the relationship between miR-22 expression level and radiochemother-apy sensitivity in patients with non-small cell lung cancer.Methods A total of 103 patients with non-small cell lung cancer admitted to the First Affiliated Hospital of Hebei North University from May 2022 to May 2023 were retrospectively selected as the study group.In addition,50 healthy people who underwent physical examination and retained blood samples in the First Affiliated Hospital of Hebei North University during the same period were selected as the control group.The expression level of serum miR-22 was detected and com-pared between the study group and the control group.According to the sensitivity results of chemoradiothera-py,patients with complete response and partial response were included in the sensitive group,and patients with stable disease and disease progression were included in the insensitive group.The clinical characteristics of the sensitive group and the insensitive group were compared.Multiple linear regression was used to analyze the effect of different clinical characteristics on the expression level of miR-22.Multivariate Logistic regression was used to analyze the influencing factors of radiochemotherapy sensitivity in patients with non-small cell lung cancer.The receiver operating characteristic(ROC)curve was drawn to analyze the predictive value of miR-22 expression level for radiochemotherapy sensitivity.Results The expression level of miR-22 in the study group was 1.32±0.11,which was lower than 2.03±0.32 in the control group,and the difference was statistically significant(t=20.244,P＜0.05).There was no significant difference in the expression level of miR-22 in non-small cell carcinoma patients with different age,gender,body mass index,Eastern Cooperative Oncology Group(ECOG)performance score and family genetic history(P＞0.05).The expression levels of miR-22 in patients with squamous cell carcinoma,TNM stage Ⅲ,lymph node metastasis,and smoking history were significantly higher than those with adenocarcinoma,TNM stage Ⅱ b,no lymph node metastasis,and no smoking history(P＜0.05).Multiple linear regression analysis showed that TNM stage,lymph node metasta-sis and smoking history were the influencing factors of miR-22 level in patients with non-small cell lung cancer(P＜0.05).Among 103 patients with non-small cell lung cancer,58 patients were sensitive to radiotherapy and chemotherapy and were included in the sensitive group.Forty-five non-sensitive cases were included in the non-sensitive group.The expression level of miR-22 in the sensitive group was(1.79±0.26),which was high-er than(1.15±0.39)in the non-sensitive group,and the difference was statistically significant(t=12.046,P＜0.05).There were significant differences in pathological type,TNM stage,lymph node metastasis,and smoking history among patients with different radiochemotherapy sensitivity(P＜0.05).Multivariate Logis-tic regression analysis showed that pathological type,TNM stage,lymph node metastasis and smoking history were the influencing factors of radiochemotherapy sensitivity in patients with non-small cell lung cancer(P＜0.05).ROC curve analysis showed that the area under the curve(AUC)of miR-22 expression level for predic-ting the sensitivity of chemoradiotherapy was 0.957(95％CI:0.921-0.993),and the sensitivity and specifici-ty were 89.3％and 95.3％respectively.Conclusion The expression level of miR-22 is abnormally decreased in patients with non-small cell lung cancer,and its level is related to the sensitivity of radiotherapy and chemo-therapy,which has excellent value in predicting the sensitivity of radiotherapy and chemotherapy.关键词
miR-22/非小细胞肺癌/放化疗/临床特征/回归分析Key words
miR-22/non-small cell lung cancer/chemoradiotherapy/clinical characteristic/regres-sion analysis分类
医药卫生引用本文复制引用
马方旭,郭立娟,张明洋,邹芳,张新..miR-22表达水平与非小细胞肺癌患者放化疗敏感性的关系[J].检验医学与临床,2024,21(13):1864-1869,6.基金项目
河北省2023年度医学科学研究课题计划(20231415). （20231415）
